The Global Fund is an international organization that finances disease treatment and prevention ... face deep internal pressure to not blow out the deficit with the bill they are planning ...

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...